Paper Details
- Home
- Paper Details
Overestimation of the effect of (fos)aprepitant on intravenous dexamethasone pharmacokinetics requires adaptation of the guidelines for children with chemotherapy-induced nausea and vomiting.
Author: Enters-WeijnenCatherine F, HuitemaAlwin D R, LalmohamedArief, NijstadA Laura, RosingHilde, TibbenMatthijs M, TissingWim J E, ZwaanC Michel, de Vos-KerkhofEvelien, van de WeteringMarianne D
Original Abstract of the Article :
Label="PURPOSE" NlmCategory="OBJECTIVE">Chemotherapy-induced nausea and vomiting (CINV) are common side effects in pediatric oncology treatment. Besides 5-HT<sub>3</sub>-antagonists, both dexamethasone and aprepitant are cornerstone drugs in controlling these side effects. Based on results of adult ...See full text at original site
Dr.Camel's Paper Summary Blogラクダ博士について
ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。
* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。
引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9607815/
データ提供：米国国立医学図書館（NLM）
(Fos)aprepitant and Dexamethasone: A Complex Interaction in Pediatric Oncology
Chemotherapy-induced nausea and vomiting (CINV) are common side effects in pediatric oncology treatment. This study explores the interaction between aprepitant, a substance P/neurokinin-1 receptor antagonist, and dexamethasone, a corticosteroid, in children receiving chemotherapy. The researchers investigated the effect of aprepitant on dexamethasone pharmacokinetics to determine whether the current practice of reducing dexamethasone dose in combination with aprepitant is appropriate for children.
A Complex Landscape: Drug-Drug Interactions in Pediatrics
The study highlights the complexity of drug-drug interactions in pediatric oncology. The researchers found that aprepitant does not significantly affect dexamethasone clearance in children, challenging the current practice of reducing dexamethasone dose in combination with aprepitant. These findings have important implications for optimizing antiemetic regimens for children receiving chemotherapy.
Navigating the Desert of Pediatric Oncology: Optimizing Treatment Strategies
This study provides valuable insights into the interactions between aprepitant and dexamethasone in children with cancer. The findings suggest that the current practice of reducing dexamethasone dose may not be necessary in children receiving aprepitant. This research encourages a re-evaluation of antiemetic regimens for children, aiming to optimize treatment strategies and minimize side effects.
Dr.Camel's Conclusion
This study explores the interaction between aprepitant and dexamethasone in children receiving chemotherapy. The findings suggest that aprepitant does not significantly affect dexamethasone clearance in children, challenging the current practice of reducing dexamethasone dose. This study encourages a re-evaluation of antiemetic regimens for children, aiming to optimize treatment strategies and minimize side effects. Just as a camel adapts to the changing desert landscape, healthcare providers must continuously adapt their treatment approaches to ensure the best possible outcomes for their young patients.
Date :
- Date Completed 2022-12-05
- Date Revised 2022-12-05
Further Info :
Related Literature
English
This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.